GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies

Bone Marrow Transplant. 2016 Dec;51(12):1642-1643. doi: 10.1038/bmt.2016.254. Epub 2016 Oct 10.

Authors

A Nazha¹, L Rybicki¹, D Abounader¹, B Bolwell¹, R Dean¹, A T Gerds¹, D Jagadeesh¹, B K Hamilton¹, B T Hill¹, M Kalaycio¹, H Liu¹, B Pohlman¹, R Sobecks¹, M A Sekeres¹, N S Majhail¹

Affiliation

¹ Department of Hematology and Oncology, Blood and Marrow Transplant Program, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.

PMID: 27721371
DOI: 10.1038/bmt.2016.254

No abstract available

MeSH terms

Age Factors
Aged
Female
Graft vs Host Disease / prevention & control*
HLA Antigens / chemistry
Hematopoietic Stem Cell Transplantation / methods*
Humans
Kaplan-Meier Estimate
Leukemia, Myeloid / mortality
Leukemia, Myeloid / therapy*
Leukemia, Myeloid, Acute / therapy
Leukemia, Myelomonocytic, Chronic / therapy
Male
Middle Aged
Myelodysplastic Syndromes / therapy
Neoplasm Recurrence, Local
Retrospective Studies
Risk Factors
Time Factors
Transplantation Conditioning / methods
Transplantation, Homologous / methods
Treatment Outcome

Substances

HLA Antigens